Company intelligence / Profile preview

BioLumix

Ann Arbor, Michigan, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

BioLumix developed a commercial automated platform for rapid detection and enumeration of microorganisms in raw materials and finished products—primarily for food, nutraceutical, and pharmaceutical applications. Its technology quickly detects bacteria and fungi; results for bacteria are available in under 24 hours, and for yeast in under 48 hours. BioLumix was acquired by Neogen Corporation in September 2014.

Modalities: Device
Industry: Molecular Diagnostics

Partnerships

Neogen (acquirer/strategic partner)

Beyond the preview

Go deeper on BioLumix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioLumix.

Explore the full profile